Overview

To Evaluate the Pharmacokinetics and Safety of Yimitasvir Phosphate Capsules in Subjects With Moderate and Severe Liver Function Impairment and in Healthy Subjects

Status:
Recruiting

Trial end date:
2022-10-30

Target enrollment:

Participant gender:

Summary

To evaluate the pharmacokinetics and safety of Yimitasvir phosphate capsules in subjects with moderate and severe liver function impairment and healthy subjects in a single-center, non-randomized, open, single-dose administration

Phase:

Phase 1

Details

Lead Sponsor:

Sunshine Lake Pharma Co., Ltd.

Treatments:

Yimitasvir